The global spinal muscular atrophy market size was valued at US$ 884 million in 2017 and is expected to witness a robust CAGR of 12.4% over the forecast period (2018–2026).

Spinal muscular atrophy (SMA) is a genetic disorder that affects the control of muscle movement. It is caused due to loss of specialized nerve cells, called motor neurons, in the spinal cord and brainstem. The loss of motor neurons leads to weakness and atrophy of muscles used for activities such as sitting up, ... Read more

Spinal Muscular Atrophy Market– A Genetic Disorder Affecting Part of the Nervous System

Spinal muscular atrophy (SMA) is a genetic disorder that affects the control of muscle movement. It is caused due to loss of specialized nerve cells, called motor neurons, in the spinal cord and brainstem. The loss of motor neurons leads to weakness and atrophy of muscles used for activities such as sitting up, walking, crawling, and controlling head movement. In severe cases, the ... Read more

Spinal muscular atrophy is a genetic disorder disease that causes weakness and wasting (atrophy) it appears mostly in newborn children. Loss of specialized nerve cells (motor neurons) that control muscle movement is the reason for this disease. Due to this disease, an individual cannot walk, eat and breathe properly. The muscle weakness usually worsens as the child grows up. SMA disease can occur in any race or gender. 1 out of 11,000 babies is affected by this disease. ... Read more

The global spinal muscular atrophy market witnesses substantial competition with the presence of a considerable number of market participants of varying sizes, says Transparency Market Research (TMR) in a new market study. Savvy players are engaged in developing novel drug formulations, the success rate of which impacts market share, and trust of these companies among ... Read more

The global Spinal Muscular Atrophy Market is estimated to be valued at US$ 1,600.6 million in 2022 and is expected to exhibit a CAGR of 13.3% over the forecast period 2022-2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:
Spinal Muscular Atrophy (SMA) is a rare genetic disorder characterized by the loss of motor neurons, leading to progressive muscle weakness and atrophy. The market for SMA treatment is witnessing ... Read more

Spinal muscular atrophy (SMA) is a genetic neuromuscular disease that attacks the motor neurons associated with muscles used for activities like crawling, walking, head and neck control, and swallowing. Gene therapy is emerging as a promising approach to treat SMA by delivering a functional copy of the SMN1 gene to produce more SMN protein.

The global Spinal Muscular Atrophy Market is estimated to be valued at US$ 2089.13 Bn in 2024 and is expected to exhibit a ... Read more

Spinal muscular atrophy (SMA) is a genetic disease that affects the nerves that control voluntary muscle movement. SMA causes muscles used for activities like crawling, rolling over, sitting up, and walking to become weaker over time. The global spinal muscular atrophy market consists of therapeutic products used for the treatment of SMA. Key products in the market include nusinersen and onasemnogene abeparvovec. Nusinersen is the first and only approved drug that addresses the underlying ... Read more